Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study
Authors' conclusion
Dapagliflozin exerted robust cardioprotective effects against PMI/4aMI in patients with T2DM and CCS undergoing PCI, particularly among patients in high-risk subgroups, but it did not significantly reduce the risk of CI-AKI. These findings support the peri-PCI use of dapagliflozin to mitigate cardiac risk while highlighting the need for further research to elucidate its renal effects in this population.
Study context
- Population
- Patients with T2D and chronic coronary syndrome undergoing percutaneous coronary intervention (PCI) at a tertiary hospital (January 1, 2018, to March 31, 2022)176 vs 176 after propensity score matching (PSM)
- Participants
- 1,430 patients
- Exposure
- Dapagliflozin vs control
- Dapagliflozinn = 176
- Controln = 176reference
- Outcome
- Cardiac outcomes (PMI/4aMI) and renal outcomes (eGFR and CI-AKI)
Methodological detailsregistry, single tertiary hospital database, 1:1 propensity score matching
- Registry
- Single tertiary hospital database
- 1:1 propensity score matching
Main finding
As reported in the abstract
PMI/4aMI rate
Dapagliflozin vs ControlEstimate (95% CI)P value
post-PSM
OR 0.660(0.531–0.821)
P < 0.001After adjustment
adjusted OR 0.436(0.285–0.668)
P < 0.001Observational data: associations, not effects.
Further findings
| Outcome | Dapagliflozin | Control | OR (95% CI) | P value | |
|---|---|---|---|---|---|
| PMI/4aMI rate pre-PSMpre-PSM | 39.78% | 66.99% | 0.862 (0.823–0.904) | P < 0.001 | |
| 0.512Odds ratio (log scale) |
- Renal outcomes (CI-AKIESUR and CI-AKIKDIGOs) · before or after PSM or after adjustment
- all p > 0.05
PMI/4aMI by subgroup
- Increased protection in patients aged ≥ 65 years, with multivessel disease and with higher contrast volumes
Renal outcomes (CI-AKIESUR and CI-AKIKDIGOs)
- Not significantly different before or after PSM or after adjustment
Original publication
Cardiorenal protection with dapagliflozin in patients with type 2 diabetes mellitus and chronic coronary syndrome undergoing percutaneous coronary intervention: a registry cross-sectional study. Cardiovasc Diabetol. Published 26 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →